 "Nomura upgrades Ranbaxy Labs to 'buy', shares gain")
Shares in Ranbaxy Laboratories gained after Nomura upgraded the stock to "buy" from "neutral" and raised its target price to Rs 475 rupees from Rs 415.
Nomura cited recent underperformance and a positive take away from management interaction as reasons for the upgrade.
"The organisational restructuring has brought greater clarity and there is strong commitment towards improvement in margins, in our assessment," Nomura said in a note.
The research house noted positive catalysts include FDA approval for Diovan and other key products as well as improvement in base business margins.
Ranbaxy shares up 2.1% percent at Rs 411.60.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app